SYNACT.ST STO
SynAct Pharma AB
1W: +2.9%
1M: +2.1%
3M: -7.8%
YTD: -13.6%
1Y: -3.5%
3Y: -82.2%
5Y: -83.8%
kr 17.80 ($1.77)
+0.62 (+3.61%)
Weekly Expected Move ±6.3%
kr 16
kr 17
kr 18
kr 19
kr 20
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
No convergence signal
Key Statistics
Market Capkr 945.4M ($94.2M)
52W Range7.05-25.3
Volume77,385
Avg Volume354,641
Beta0.76
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJeppe Ovli Ovlesen
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2016-07-11
Websitesynactpharma.com
Scheelevägen 2
Lund, SN 223 63
SE
Lund, SN 223 63
SE
46 28 44 75 67
About SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Ãrebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Latest News
No recent news
Recent Insider Trades
No insider trades found